New Research Data Across DXd ADC Portfolio at WCLC Showcases Daiichi Sankyo s Continued Commitment in Lung Cancer will be featured as late-breaker presentation
Updated TROPION-PanTumor01 results of datopotamab deruxtecan in patients with advanced NSCLC to be highlighted
Biomarker analysis from phase 1 trial of patritumab deruxtecan in patients with previously treated metastatic or locally advanced EGFR mutated NSCLC to be presented
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it will present new research data across its DXd ADC portfolio including ENHERTU (trastuzumab deruxtecan), datopotamab deruxtecan (Dato-DXd; DS-1062) and patritumab deruxtecan (HER3-DXd) at the 2020 World Conference on Lung Cancer (WCLC20) virtual conference to be held January 28-31, 2021.